Seminars in Hematology
Volume 47 , Pages S11-S14 , April 2010

Novel Agents in Development for Peripheral T-Cell Lymphoma

  • Owen A. O'Connor

      Affiliations

    • Corresponding Author InformationAddress correspondence to Owen A. O'Connor, MD, PhD, New York University Cancer Institute, NYU Langone Medical Center, 522 First Ave, Smilow Room 1120, New York, NY 10016

References 

  1. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–4364
  2. Allos Therapeutics I. ODAC briefing document—Pralatrexate injection (US Food and Drug Administration, 2009). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180636.pdfAccessed January 11, 2010
  3. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115
  4. Piekarz R, Wright J, Frye R, et al. Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) [abstr 1567]. Blood. 2008;112:555
  5. Toner LE, Vrhovac R, Smith EA, et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:924–932
  6. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351–1353
  7. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–187
  8. Horwitz SM, Vose JM, Advani R, et al. Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase I results [abstr 1674]. Blood. 2009;114:667
  9. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–4297
  10. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008;19:2079–2083
  11. Paoluzzi L, Scotto L, Seshan VE, O'Connor OA. Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) [abstr 8584]. J Clin Oncol. 2009;27:454s
  12. Wilson W, O'Connor O, Roberts AW, et al. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [abstr 8574]. J Clin Oncol. 2009;27:452s
  13. Wilson WH, O'Connor O, Czuczman MS, et al. Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies [abstr 2108]. Blood. 2008;112:734
  14. Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008;112:2906–2916
  15. Dueck GS, Chua N, Prasad A, et al. Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases [abstr 8524]. J Clin Oncol. 2009;27:439s
  16. Sakiyama T. [Purine nucleoside phosphorylase (PNP) deficiency]. Nippon Rinsho. 1996;54:3328–3332
  17. Furman RR, Gore L, Ravandi F, Hoelzer D. Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a phase II study (interim report) [abstr 1851]. Blood. 2006;108:524a
  18. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer. 1991;64:903–906
  19. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–187
  20. Enblad G, Hagberg H, Erlanson M. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–2924
  21. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004;100:342–349
  22. Dang NH, Pro B, Hagemeister FB. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007;136:439–447
  23. Reiman T, Finch D, Chua N, et al. First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma. Blood. 2007;110:Abstract 2579
  24. Czuczman MS, Porcu P, Johnson J, et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007;48:97–103

 STATEMENT OF CONFLICT OF INTEREST: Dr O'Connor discloses the following relationships: Contracted Research: Allos, Millennium, Abbott, Lily.

PII: S0037-1963(10)00015-6

doi: 10.1053/j.seminhematol.2010.01.014

Seminars in Hematology
Volume 47 , Pages S11-S14 , April 2010

Article Tools